Shanna Fuld

About the Author Shanna Fuld

Shanna J. Fuld is a journalist specializing in finance. Born and raised in Queens, New York, she’s been avoiding dates with finance guys for years – only to find herself becoming one. The former NY1er worked as a videographer, assignment editor and writer for the beloved local news channel before joining the Smarter Analyst team.

This Analyst Has Patience When it Comes to Apple (AAPL) Stock; Here’s Why

Wedbush analyst Daniel Ives takes a metaphoric sigh after learning some negative news coming out of China’s People’s Court, which granted two preliminary …

Roku (ROKU) Stands Ground Against Potential Apple TV Competition; Analyst Weighs in on the Stock

Rumors are spreading that Apple is considering making a lower-priced connected TV dongle for its Internet TV platform to-be. Though it is unclear …

Laying Out a Realistic Bear Case for General Electric (GE) Stock: Deutsche Bank

General Electric (GE) has been a symbol of America’s strength. But over the past few years, the company has, instead, been a symbol …

MYOS RENS Technology (MYOS) Stock Fires Up to the Roof; Here’s Why

MYOS RENS Technology (MYOS) stock is soaring — up over 50% since news broke today that The Vitamin Shoppe is picking up its product …

Should You Blindly Follow Facebook (FB) Stock Along the Buyback?

During a time where Facebook (FB) management is under fire, negative press has taken a toll on its stock and even users feel …

Square’s (SQ) Proven Track Record Should Be Enough Incentive to Buy Stock

Top blogger Bill Maurer is encouraging investors to buy Square (SQ) shares after the stock fell around 7% amid a market selloff and …

Gilead Sciences (GILD) Stock: Analyst Believes New CEO Could Be a Game-Changer

Congrats! Gilead Sciences (GILD) has just appointed Daniel O’Day as the Chief Executive Officer of the pharmaceutical giant.

MacroGenics (MGNX) Stock Tumbles After Clinical Hold on Early-Stage Study — Yet This Analyst Bulls Ahead

After the markets closed Friday, MacroGenics (MGNX) announced a partial clinical hold on its Phase 1 monotherapy study of  MGD009, a bispecific antibody developed under …

A Glimpse Into the Cannabis Stocks’ World

Investing in the marijuana industry may have seemed taboo a few years back, but as more states are making recreational marijuana legal with …

Marinus Pharmaceuticals (MRNS) Sparks Optimism Among Investors; Here’s Why

Marinus Pharmaceuticals (MRNS) just released positive results from its Phase 2 clinical trials, which evaluated ganaxolone intravenous (IV) (called the Magnolia Study) and …